When Trial Money Comes From Outside the Sponsor: What the J&J-Ollin-Blackstone Structure Means for Site Ops
J&J's $2.2B Ollin buyout pairs with a Blackstone funding deal, and that split ownership of trial money creates site...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
J&J's $2.2B Ollin buyout pairs with a Blackstone funding deal, and that split ownership of trial money creates site...
The EMPIRICAL trial reveals CMV as a hidden killer in HIV-positive infants with severe pneumonia, forcing a rethink of...
WCG launches tools to reduce protocol complexity burden on trial sites by surfacing operational risk during the design stage...
MAIA's ateganosine-cemiplimab combination demonstrates sustained efficacy in third-line NSCLC patients who progressed on prior immunotherapy and chemotherapy.
Exaluren restores kidney collagen in Alport syndrome Phase 2a study, showing measurable protein increases and podocyte structural improvements in...
J&J's $2.2B Ollin buyout and $750M Blackstone funding deal create an immediate Phase 3 integration challenge, here's what sponsor...
At a CDER webinar on drug interaction labeling, FDA officials drew the lines sponsors most often blur: contraindicate versus...
Medrio launches connected CTMS to automatically integrate EDC and eTMF data, reducing manual reconciliation and integration costs for clinical...
Prelude Therapeutics advances PRT13722 into Phase 1 testing with $142.7M in cash, managing three parallel clinical programs simultaneously.
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...